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Abstract
A critical factor in the transmission and pathogenesis of Toxoplasma gondii is the ability to 
convert from an acute disease-causing, proliferative stage (tachyzoite), to a chronic, dormant stage 
(bradyzoite). The conversion of the tachyzoite-containing parasitophorous vacuole membrane into 
the less permeable bradyzoite cyst wall, allows the parasite to persist for years within the host to 
maximize transmissibility to both primary (felids) and secondary (virtually all other warm-blooded 
vertebrates) hosts. This review presents our current understanding of the latent stage, including the 
factors that are important in bradyzoite induction and maintenance. Also discussed are the recent 
studies that have begun to unravel the mechanisms behind stage switching.
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INTRODUCTION
Toxoplasma gondii is an obligate intracellular protozoan parasite capable of infecting warm-
blooded vertebrates world-wide [1]. Although the parasite cannot survive outside the host 
cell, it has a significantly high transmissibility. It is estimated that approximately one third of 
the human population is infected with Toxoplasma [2]. It is one of the most widespread 
parasites due to its large range of host species and ability to transmit between hosts through 
diverse routes [3].
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Toxoplasma belongs to the phylum Apicomplexa, which includes other important pathogens 
such as Plasmodium, Eimeria, Babesia, Neospora, Sarcocystis and Cryptosporidium [4–6]. 
Upon initial infection of an immunocompetent host with Toxoplasma, an often 
asymptomatic acute infection is followed by establishment of chronic infection, which is 
marked by the formation of intracellular tissue cysts. These cysts can persist within the host 
tissues throughout the life of the host, maintained in the quiescent state by its immune 
system. Upon immune suppression, the bradyzoites in the cyst will transition back into 
proliferating tachyzoites and can lead to devastating tissue destruction. Reactivated 
toxoplasmosis is a major concern in HIV-infected individuals and other 
immunocompromised patients [7]. In most cases, due to the proclivity of the latent 
bradyzoite to reside in central nervous system tissues, encephalitis is usually the main cause 
of death after reactivation of infection [8]. In addition, Toxoplasma tachyzoites are capable 
of crossing the placental blood barrier to be transmitted vertically from mother to fetus. 
Vertical transmission can occur if an immunologically naïve woman becomes infected with 
the parasite during her pregnancy, and can cause serious congenital birth defects or 
spontaneous abortion [6, 9]. Ocular toxoplasmosis is also a common manifestation of 
Toxoplasma, in which the retina of the eye may be destroyed in both healthy and 
immunocompromised individuals [10]. Ocular toxoplasmosis was traditionally thought to 
stem from reactivation of a congenital infection, but acquired infection is now also 
appreciated to be a main cause of this disease [11], particularly in South America. 
Toxoplasma has also been linked with water borne outbreaks in humans and deaths in 
marine wildlife due to contamination of water with oocysts [12–14], which has led the 
parasite to being classified as a Category B Biodefense pathogen by NIAID.
A crucial event for parasite transmission and pathogenesis is the stage conversion between 
the actively replicating tachyzoites and the encysted bradyzoites. Conversion to a dormant 
tissue cyst augments parasite persistence inside the host, which in turn, increases the chances 
of transmission through predation. Bradyzoites therefore provide Toxoplasma with 
extraordinary flexibility with respect to transmission, allowing the parasite to bypass its 
sexual stage in order to disseminate [3]. Of clinical relevance, the bradyzoite cysts appear to 
be refractory to current available drug treatments, giving rise to chronic infection that 
presently cannot be eradicated.
CHARACTERISTICS OF THE BRADYZOITE CYST
Tissue cysts are intracellular structures that may develop in any visceral organ; however, 
they exhibit tropism for neural and muscle tissues. In vivo, cysts are most commonly 
detected in the brain, the eye, and in both skeletal and cardiac muscles [8]. Within the central 
nervous system (CNS), cysts have been detected in neurons, astrocytes, and microglia [15–
17], although recent studies show that parasites primarily interact with neurons in mice [18, 
19].
The size of immature cysts has been estimated to be about 5 μm with at least two parasites 
inside, indicating that cyst wall formation is an early event in bradyzoite development [20–
23]. Furthermore, using bioluminescence imaging technology in combination with parasites 
expressing luciferase under the control of a bradyzoite-specific gene promoter, it was 
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demonstrated that in vivo formation of bradyzoites commences as early as one day post-
infection [24]. As the cyst matures, changes in its size may be observed due to bradyzoite 
replication within the cyst [25]. Mature tissue cyst size and shape is variable; on average a 
mature brain cyst is spherical, about 10–70 μm in diameter and the number of parasites 
within the cyst may reach the thousands. In muscle tissues, cysts are generally more 
elongated in length and may reach a size up to 100 μm [8].
A number of major ultrastructural differences have been observed between the tachyzoite 
and bradyzoite stages. Bradyzoites are more slender than tachyzoites and have a pronounced 
crescent shape [26]. Bradyzoites contain a nucleus located at their posterior end and have 
electron dense rhoptry organelles and numerous micronemes [8, 16, 27]. Furthermore, 
bradyzoites contain amylopectin granules that stain red with periodic acid Schiff (PAS) [8]. 
It has been reported that in vitro differentiated bradyzoites may lose the parasite’s 
apicoplast, a non-photosynthetic plastid-like organelle [22, 28]. Mature bradyzoites 
represent a growth-arrested stage of the parasite with a uniform 1N content nuclear DNA 
[29]. Although this stage is generally considered to be quiescent, it may still be motile. In 
vitro bradyzoites have been observed exiting from an existing cyst to invade a new host cell 
and establish a new cyst [22]. This feature could explain the clusters of cysts that have been 
observed in vivo as well as the increase in cyst burdens in chronically infected mice. 
Recently, a novel method for isolating tissue cysts from brains of infected mice has been 
developed and has permitted a detailed study of in vivo cyst characteristics [30]. Analysis of 
these enriched cysts by immunostaining for a parasite surface protein, found that clusters of 
parasites within a subset of cysts were undergoing cell division in an asynchronous manner, 
providing some of the first direct evidence that tissue cysts are more dynamic than 
previously believed [30].
Transformation of the parasitophorous vacuole membrane into the cyst wall
The formation of the cyst wall and the matrix material provide a physical barrier to host 
immune factors. The cyst wall is visible as a reinforcement of the parasitophorous vacuole 
membrane (PVM) that occurs beneath this membrane [16]. Typically the PVM that contains 
the cyst is elastic and thin (<0.5 μm), consisting of chitin or similar polysaccharides and 
glycoproteins that can be detected using various fluorescently labeled lectins [31–33]. The 
agglutinin from Dolichos biflorus (DBA) that recognizes α-linked N-acetyl galactosamine 
has high affinity for the bradyzoite cyst wall structure and is regularly used to detect cysts in 
tissue culture (Fig. 1). Currently, only a few components of the bradyzoite cyst wall have 
been identified and their molecular functions remain unclear. CST1, a glycoprotein 
recognized by DBA, localizes in the cyst wall under the PVM [33, 34]. CST1 was recently 
identified as being a O-glycosylated protein with a mucin domain, previously annotated as 
SRS44 and disruption of the gene results in impaired cyst formation and extremely fragile 
cysts [28]. Dense granule proteins (GRA proteins) have also been found in the bradyzoite 
cyst wall [34]. At the bradyzoite stage, GRA5 is predominantly localized to the modified 
PVM rather than the granular material that precipitates underneath this membrane [23, 34]. 
The other GRA proteins that have been observed in the cyst wall so far are GRA1, GRA2, 
GRA3, GRA6 and GRA7 [23, 34–36]. MAG1 (Matrix antigen 1) is another cyst wall and 
matrix specific antigen [37]. Notably, MAG1 is also detected inside the parasitophorous 
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vacuole of the tachyzoite stage but is present in significantly lower abundance, suggesting 
that it has an important role in the formation of the bradyzoite cyst wall [34, 38]. Recently, 
three novel cyst wall proteins were identified: a bradyzoite pseudokinase (BPK1), a 
microneme adhesive repeat domain-containing protein 4 (MCP4) and a 
proteophosphoglycan [39–41], but the functions of these proteins have yet to be resolved. 
Further characterization of the cyst wall and its components are required to understand the 
molecular mechanisms of tissue cyst development.
Identification of genes contributing to bradyzoite development
Bradyzoites express certain genes exclusive to this stage of the life cycle. The findings that 
bradyzoites express specific antigens such as surface antigen 4 (SAG4); bradyzoite surface 
antigen, BSR4; surface antigen 2/2D (SAG2/2D), matrix antigen 1 (MAG1); 116-kDa cyst 
wall antigen (CST1); bradyzoite antigens 1–5 (BAG 1/5), specific metabolic enzyme 
isoforms (lactate dehydrogenase 2, LDH2; enolase 2, ENO1) [42–51] have led to extensive 
research focused on describing the function of bradyzoite-specific genes.
Initial attempts tried to identify genes that are specifically expressed or induced during 
Toxoplasma stage conversion. In an early study, a cDNA library was constructed from 
mRNA isolated from brain cysts in chronically infected mice. Screening of this expression 
library in bacteria with a pool of polyclonal antibodies against bradyzoite antigens led to the 
identification of several bradyzoite-related genes such as mag1 [37], bag1 [45] and ldh2 [46, 
47]. Parallel studies using material from in vitro differentiated bradyzoites confirmed the 
presence of the bradyzoite marker BAG1 [43] as well as other proteins, such as SAG4 [52]. 
Expressed sequence tag (EST) libraries from both in vitro- and in vivo-prepared bradyzoites 
have also been used for the detection of numerous stage specific genes [53]. Another 
approach employed a subtractive cDNA library to identify genes that were exclusively 
expressed in bradyzoites, many of which are involved in crucial cellular processes such as 
metabolism, protein folding, and DNA repair [49]. Promoter trapping screens have also been 
effective for the identification of bradyzoite-specific genes [32, 54, 55]. These screens have 
led to the detection of several bradyzoite gene loci, for example the bradyzoite surface 
antigen bsr4 (p36) [55]. More recently, deep RNA sequencing has allowed for a more global, 
non-biased approach to determining the patterns of gene expression in tachyzoites versus 
bradyzoites. Analysis of the total RNA from forebrains from both acute and chronically 
infected mice identified 547 parasite genes significantly regulated between the two stages of 
disease. In addition to previously reported alterations to metabolic gene expression, this 
approach also identified many novel stage-specific markers. From these results, it appears 
that the parasites downregulate one set of sag-related surface markers in the tachyzoite to 
upregulate another set of similar genes in the bradyzoite. A large proportion (~50%) of the 
significantly upregulated genes in the bradyzoite were hypothetical genes, hinting at a 
number of parasite-specific processes that could be targeted with inhibitors as therapies 
against chronic toxoplasmosis [56].
Improvements in the tools facilitating molecular genetics analyses in Toxoplasma have 
allowed the construction of an increasing number of bradyzoite-specific gene knockouts. 
The construction of the bag1 knockout strain was one of the first attempts to disrupt a 
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bradyzoite-specific gene [57, 58]. Other knockouts that have been described include the 
membrane proton-ATPase (PMA1) [59], the bradyzoite surface antigen SRS9 [60], the dense 
granule proteins GRA4 and GRA6 [61], the genetic locus ROP4/7 [61], the plant-like 
Apetala-2 transcription factors AP2XI-4, AP2IX-9, AP2IX-4, AP2IV-4 and AP2IV-3 [62–
66], and the bradyzoite secreted pseudokinase 1 (BPK1) [39]. In all knockouts made to date, 
the production of cyst-like structures was observed in vitro, suggesting that individually 
these genes are not required for initiating bradyzoite switching. Nevertheless, defects in cyst 
morphology, cyst number, in vivo cyst formation and transmission of infection, indicate that 
many of these genes contribute significantly to cyst development.
In one study, chemical mutagenesis was used to identify tachyzoite to bradyzoite 
interconversion defective (Tbd−) mutants [67]. Other approaches applied insertional 
mutagenesis and reverse genetic screens [41, 68–70]. Finally, another study employed a 
signature-tagged insertional mutagenesis screen designed to isolate generally avirulent 
parasites. These clones were subsequently screened for reduced in vivo cyst formation in 
order to identify genes required only for pathogenesis [71]. Despite differences in the type of 
mutagenesis performed and the methods of selection of defective parasites, this work from 
different groups has collectively identified factors that may contribute to bradyzoite 
differentiation. However, most of the candidates have yet to be verified in independent 
studies as having a clear role in cyst formation. Moreover, some study designs may have 
isolated mutants resistant to in vitro differentiation stresses, and the genes may have more to 
do with stress-resistance than differentiation. Despite these caveats, the genes and their 
associated bradyzoite phenotypes that have been identified from these screens are discussed 
in Table 1.
Further investigation is necessary to describe the molecular mechanisms of Toxoplasma 
differentiation. Individual studies of the genes implicated in bradyzoite development have 
been informative but the complete picture of this developmental pathway is still elusive. 
Nevertheless, the advent of techniques such as mRNA deep sequencing will allow full-scale 
expression profiling to compare both the tachyzoite and bradyzoite developmental stages 
and will refine our current understanding of this clinically relevant developmental pathway. 
Importantly, new in vitro models need to be pursued to delineate the phenomenon of stress-
induced and spontaneous differentiation, and candidate genes need to be supported by in 
vivo data.
Metabolism in the bradyzoite stage
As the parasites transform from replicating tachyzoites to latent bradyzoites, changes in 
parasite metabolism have been observed. It may be assumed that these changes allow the 
parasites to remain dormant for long periods of time and are mediated by upregulation of 
bradyzoite-specific forms of various metabolic enzymes, particularly those involved in 
dealing with oxygen radical metabolism and carbohydrate metabolism. The formation of the 
amylopectin storage granules upon differentiation to bradyzoites indicates that the parasites 
modulate carbohydrate metabolism during stage switching. Tight regulation of amylopectin 
levels is required for maintaining chronic infection in mice [30]. Site-directed mutagenesis 
of an enzyme responsible for amylopectin digestion, the Toxoplasma glycogen 
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phosphorylase (TgGP), was performed to determine the importance of amylopectin 
metabolism in both tachyzoite and bradyzoite stages. Mutation of a phosphorylated serine to 
inactivate (S25A) TgGP led to excessive accumulation of amylopectin. Conversely, mutation 
of this residue to a phosphoserine-mimetic (S25E) caused amylopectin deficiency. Although 
both mutant lines were capable of differentiation in vitro, they both displayed significantly 
reduced cyst burdens in the brains of chronically infected mice compared to the parental 
line, indicating that maintaining the appropriate levels of amylopectin is necessary for 
establishing a persistent chronic infection [30, 72].
It also appears that bradyzoites rely on anaerobic glycolysis for generation of ATP since they 
do not retain a functional TCA cycle [48]. Further evidence for changes in carbohydrate 
metabolism comes from differential regulation of bradyzoite-specific isoforms of lactate 
dehydrogenase (LDH2), glucose-6-phosphate dehydrogenase (G6-PI), and enolase-1 
(ENO1), all of which display different stability and enzymatic properties compared to their 
tachyzoite counterparts [48, 73]. The bradyzoite-specific LDH2 isoform is hypothesized to 
be important for establishing chronic infection in the host, since mice infected with LDH2-
knockdown parasites displayed much lower numbers of brain cysts compared to the parental 
line [74].
Persistence of chronic Toxoplasma infection also relies on continued autophagy and turnover 
of old organelles or cellular components. Cathepsin protease L is not required for tachyzoite 
replication or the initial stages of bradyzoite development, but is critical for viability of the 
mature tissue cyst. Genetic or chemical ablation of cathepsin protease activity caused an 
accumulation of undigested autophagosomes and loss of bradyzoite viability indicating that 
the parasites must recycle proteins and organelles to persist [75].
The long-lived latent cysts must also be capable of dealing with exposure to various radicals 
and reactive metabolic byproducts; consequently, enzymes that cope with this stress are 
upregulated during bradyzoite formation e.g. thioredoxin and glutathione peroxidase [53].
EXPERIMENTAL MODELS OF CYST FORMATION
Strain differences
Genetic analysis of Toxoplasma isolates from Europe and North America has identified 
three predominant lineages of the parasite designated Types I, II, and III, which resulted 
from a single genetic cross approximately 10,000 years ago [76]. The three strains differ in 
their growth rate, virulence, their ability to traverse or to pass through epithelial layers 
(transmigration), and their capacity to form cysts [77, 78].
Type I strains generally replicate faster and, consequently, are more virulent in mice. A Type 
I strain isolated in 1939, designated “RH” after the patient from which it was isolated [79], 
is the most common laboratory strain in use. Today’s RH strain has a rapid replication rate 
and is highly amenable to genetic manipulation, making it a favored tool for the study of 
tachyzoite biology. However, RH parasites are limiting in the study of conversion from 
tachyzoite to bradyzoite. Although it has been reported that under stress conditions RH 
tachyzoites will upregulate specific bradyzoite genes and, in some reports, produce 
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bradyzoite-specific proteins or cyst wall components [80–82], the parasites are largely 
incapable of forming mature bradyzoite cysts either in vitro (in cell culture) or in vivo 
(during mouse infection). However, low-passage type I strains are capable of switching to 
bradyzoites [83], which means that extensive passage in vitro is associated with the loss of 
developmental competency [84]. Type II and Type III strains replicate at a slower rate, 
readily convert to bradyzoites, and are hypovirulent in mice, but these characteristics change 
with prolonged in vitro passage. Differences in the developmental capacity among these 
strains are influenced by adaptation to in vitro growth in HFF cells.
Genome sequence data from parasite lines of all three types has been collected and can be 
accessed at the Toxoplasma genome database (www.toxodb.org). This genome information 
has proven essential in dissection of the mechanisms and pathways for conversion from 
tachyzoite to bradyzoite forms.
Stress-induced bradyzoite formation
The early stages of the transition from tachyzoite to bradyzoite may be studied using in vitro 
culture and conditions shown to induce the conversion. These methods have been used to 
examine potential pathways associated with the early stages of bradyzoite development. 
Different kinds of stress applied to proliferating tachyzoites have been demonstrated to 
induce cyst formation.
The most commonly used method to induce bradyzoite cysts for in vitro culture is 
continuous alkaline treatment of parasite-infected host cells by adjusting the growth medium 
to pH 8.0–8.2 [80]. A brief alkaline treatment of extracellular tachyzoites prior to invasion 
has also been demonstrated to increase frequency of cyst development [85]. A number of 
other methods that involve adjustments to the culture medium or culture conditions to trigger 
stress-induced bradyzoite formation include various forms of nutrient deprivation through 
arginine starvation [86], axenic incubation [49], and depletion of pyrimidine in uracil 
phosphoribosyltransferase (UPRT)-deficient parasites grown in 0.03% CO2 [22, 81].
Bradyzoite formation may also be enhanced using heat shock as an exogenous stress [80]. 
Soete et al. (1994) observed bradyzoite formation after heat shocking host cells at 43°C 
before allowing parasites to invade at 37°C and applying an additional heat shock to the 
infected cells [80].
Chemical treatment of the parasites and host cells has also been used to apply stress and 
trigger cyst formation. Tunicamycin treatment of parasite-infected cells causes endoplasmic 
reticulum (ER) stress and subsequent bradyzoite development [87]. Chemical stress may 
also be applied using sodium arsenite [80]. Chemical inhibition of calcium-induced egress 
with the herbicide fluridone has also been demonstrated to result in a larger proportion of 
bradyzoite cysts in culture [88].
Compounds that inhibit mitochondrial function and subsequently induce oxidative stress (i.e. 
sodium nitroprusside or atovaquone) will also trigger bradyzoite development [89, 90]. 
Interferon - gamma (IFN-γ) treatment of tachyzoite infected fibroblasts will not induce 
bradyzoite development [80], but when murine macrophages are infected with Toxoplasma 
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and subsequently treated with IFN-γ, bradyzoite development commences, likely as a result 
of nitric oxide production from the activated macrophage [91].
Cyclic adenosine monophosphate (cAMP)-mediated signaling regulates a number of parasite 
processes including differentiation from tachyzoite to bradyzoite [92]. Using an engineered 
optogenic Toxoplasma strain in which cAMP levels could be controlled by photo-activation, 
Hartmann and colleagues (2013) demonstrated that a minimum level of intra-parasitic 
cAMP was required for initiation of bradyzoite formation, but increased levels of cAMP 
impaired the process indicating that cAMP-responsive factors are involved in the 
differentiation signaling pathway [92]. The importance for tightly regulated cAMP levels in 
parasite differentiation is underscored by a recent study on a cAMP-dependent protein 
kinase A homologue, TgPKA3. Knock-out of the TgPKA3 catalytic subunit led to a growth 
defect in tachyzoites and an increase in spontaneous cyst formation, in both Type I and Type 
II backgrounds. The role of TgPKA3 in cAMP levels was confirmed by rescue of the 
aberrant growth and differentiation phenotypes with the compound 3-isobutyl-1-
methylxanthine, which restores cAMP levels in the parasite [93].
Host cell determinants and spontaneous bradyzoite development
Factors in the host cell may also act as determinants of cyst development. Reviewed in [94]. 
Toxoplasma tachyzoites replicate rapidly and require sufficient levels of nutrients that are 
scavenged from the host cell to support this proliferation. If host cell metabolic conditions 
limit the supply of essential nutrients to the parasites, it will slow the replication rate and 
favor differentiation to the bradyzoite stage [91, 95]. This has been demonstrated in in vitro 
parasite culture when removal of essential nutrients such as arginine or lipoprotein (a source 
of cholesterol) from the culture medium favors bradyzoite differentiation [86, 96]. The host 
cell glycolytic flux can also influence the rate of parasite initiation of differentiation. 
Dividing host cells in high glucose conditions have an enhanced rate of glycolysis. This 
generates higher levels of lactate which was shown to favor tachyzoite replication and to 
inhibit conversion to bradyzoites [97]. Treatment of human host cells with a trisubstituted 
pyrrole called “Compound 1” prior to tachyzoite infection slowed parasite replication and 
led to the upregulation of bradyzoite-specific gene expression [98]. Although compound 1 
was originally developed as an inhibitor of cyclic guanosine monophosphate (cGMP) kinase 
[99, 100], it was found to exert its effect through host cell factors [98]. The same study also 
demonstrated that pre-stressing host cells with alkaline pH before parasite infection was 
capable of enhancing cyst formation [98].
While cellular stress is a strong mediator of tachyzoite to bradyzoite conversion, other 
factors may play a role in initiating the development of cysts. Tachyzoites of cystogenic 
Type II and Type III strains will spontaneously convert to bradyzoites in in vitro culture, 
particularly when host cells have been inoculated with a low multiplicity of infection (MOI) 
or if egressed tachyzoites are continuously removed from the culture [101]. Although 
Toxoplasma tachyzoites are capable of infecting any nucleated cell from a warm-blooded 
animal, certain cell types are more conducive to cyst formation than others [102]. 
Transcriptomic analysis of parasite gene expression during infection of a number of different 
cell types indicated greater bradyzoite specific gene expression in certain cell types such as 
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neurons or muscle cells, even in the absence of extrinsic stress. These data suggest that a 
subset of cell types are more conducive to bradyzoite formation [103]. The cell cycle stage 
of host cells that are more permissive to bradyzoite formation may be a strong influence. 
Terminally differentiated mouse myotubes (skeletal muscle fibres) restricted tachyzoite 
replication and promoted bradyzoite differentiation compared to their dividing myoblast 
progenitors [104]. Neurons are in a similar state of terminal differentiation to skeletal muscle 
cells and it is tempting to speculate that this explains the enrichment of tissue cysts in the 
CNS and muscle tissue in infected animals.
Host immunity factors and tissue cysts
Since the initiation of cyst development has been largely studied in the context of stress, it 
has been proposed that in vivo the stress applied by immune system factors during host 
infection is crucial in triggering tachyzoites to transform into bradyzoites [105]. The host 
immune system can effectively control Toxoplasma infection (for a recent review see [106]) 
but it appears that rather than specific immune effectors actively inducing chronic infection, 
a functional immune response maintains parasite in the latent bradyzoite state and that a 
dysfunctional immune response simply allows acute infection to go unchecked.
Cell-mediated immunity is vital for the restriction of Toxoplasma and the development of 
chronic infection in an immunocompetent host (reviewed in [106, 107]). Increased 
susceptibility to Toxoplasma has been observed in patients with impaired T-cells as well as 
in mice that lack B-cells, CD8+, or CD4+ T-cells [108–110]. CD4+ cells, which can activate 
CD8+ cells, have been proven to be necessary for the maintenance of CD8+ functions during 
the chronic stage of infection [111, 112].
Notably, it appears that highly virulent Toxoplasma strains have evolved strategies to inhibit 
the functions of CD8+ cells. A recent study showed that CD8+-mediated immunity is 
seriously compromised during infection by the RH strain [113]. The kinase activity of 
ROP18 in the virulent Type I strain was found to target the host activating transcription 
factor 6β (ATF6-β) for degradation [114], which resulted in downregulation of CD8+ cell-
mediated immune responses. Although RH parasites are capable of developing tissue cysts, 
infection never progresses to the chronic stage because the host immune system is rapidly 
overwhelmed by ROP18 function and tachyzoite proliferation leads to systemic infection, 
organ failure and death.
The major product of activated CD8+ [115], CD4+ T-cells [116] as well as of non-T and 
non-NK cells [117–119] is IFN-γ, a cytokine that is well-documented to be a key mediator 
of Toxoplasma infection. In contrast to wild-type mice that survive and develop chronic 
infection, IFN-γ knock-out (KO) mice succumb to infection with avirulent Toxoplasma 
strains [120]. Moreover, chronic parasite infection does not develop in mice that have been 
treated with monoclonal antibodies against IFN-γ [115, 121]. Depending on the host 
species and the cell type, IFN-γ has been proven to activate a variety of effector mechanisms 
that are required for resistance during chronic infection.
After Toxoplasma infection, IFN-γ induces the formation of reactive oxygen and nitric 
oxide (NO) metabolites in macrophages, microglia, and astrocyte cells of mice and humans 
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[122–124]. It appears that the NO by-product is a key factor for suppressing parasite 
replication and inducing bradyzoite development [89, 125–127], similarly to in vitro 
induction of bradyzoites with sodium nitroprusside, as previously discussed. However, NO is 
not an essential factor for in vivo formation of bradyzoites. Tissue cysts could develop in 
inducible nitric oxide synthase KO mice [120] as well as in mice that had been treated with 
aminoguanidine, the inhibitor of the enzyme that produces NO [128].
An IFN-γ-mediated tryptophan degradation response has been observed in human brain 
endothelial cells, HFF cells, and macrophages infected with Toxoplasma [129–131]. 
Additionally, IFN-γ-treatment of Toxoplasma-infected cells results in upregulation of 
indoleamine 2,3-dioxygenase 1 and 2 (IDO1 and IDO2), which are host enzymes that are 
responsible for degradation of tryptophan [132–134]. Since Toxoplasma is auxotrophic for 
tryptophan, upregulation of IDO1 and IDO2 restricts availability of this essential amino acid 
and thus inhibits parasite replication [135]. Parasite replication may be restored with the 
addition of exogenous tryptophan [136]. In vivo inhibition of IDO1 and IDO2 with a 
chemical inhibitor did not affect the levels of IFN-γ produced after Toxoplasma challenge, 
but treatment of chronically infected mice with IDO inhibitors led to reactivation of the 
disease and increased Toxoplasma cyst burden, demonstrating an important role for IDO 
during latent infection [134]. Notably, IDO has also recently been shown to be involved in 
host immunity against Trypanosoma cruzi and malaria [137, 138].
The host immune effector Tumor Necrosis Factor α (TNFα) has also been shown to play an 
important role in establishing chronic Toxoplasma infection [139, 140]. IFN-γ may function 
in synergy with TNFα since treatment of Toxoplasma-infected murine macrophages induces 
the expression of bradyzoite markers [89]. Interleukin 6 (IL-6) is another inflammatory 
cytokine that causes the increase of cyst numbers produced in vitro in HFF cells [141]. It 
also appears that control of both acute and chronic stages of infection depends on IL-12, a 
cytokine that drives the production of IFN-γ [115, 142, 143].
In addition to host cell background influencing spontaneous bradyzoite conversion, the 
particular in vivo distribution of cysts in brain and muscle tissues may be facilitated by 
specific local immune responses [144, 145] or potentially ineffective immune responses 
within these tissues [146]. Alternatively, organ or cell type-specific factors that trigger high 
levels of stage conversion and tissue cyst formation may contribute to enhance parasite 
persistence in these tissues. As previously mentioned, treatment of host cells with 
Compound 1 modulates host cell factors, making them more permissive to bradyzoite 
formation [98]. Treatment of host cells with Compound 1 prior to infection with Toxoplasma 
induced the upregulation of the human cell division autoantigen-1 gene (CDA-1). The 
increased expression levels of CDA-1 affected parasite replication, arresting the parasite cell 
cycle and inducing bradyzoite gene expression, directly implicating host cell factors in the 
differentiation process [98]. Furthermore, it was recently noted that the metabolic state of a 
cell, as well as non-immune secreted metabolites, could designate host cells as either 
permissive or resistant to bradyzoite development [97, 147].
Although the host immune responses play critical roles in elimination of tachyzoites and 
contribute to host environmental changes that foster tachyzoite to bradyzoite conversion and 
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maintenance of tissue cysts, it remains unclear how these signaling pathways compare to 
induction methods currently used for in vitro differentiation models. The growing 
convenience of RNA sequencing will be valuable for comparing the transcriptional 
responses of parasites during the early stages of bradyzoite development during in vivo 
infection and the commonly used in vitro induction models. Pinpointing the commonalities 
within the different models will identify the core signaling molecules that drive the transition 
to the chronic stage.
Reactivation of infection: bradyzoites to tachyzoites
The tissue cysts remain largely quiescent for the life of a host, but tachyzoites can re-emerge 
and cause toxoplasmosis in immunocompromised patients. The reactivation mechanisms 
have not been studied extensively, but it is generally assumed that abrogation of the host 
immune response results in bradyzoite to tachyzoite conversion [105]. Human 
immunodeficiency virus (HIV) patients with reduced numbers of CD4+ cells acquire 
toxoplasmosis [7, 148]. A similar course of infection occurs in chronically infected mice that 
lack CD4+ cells [109], further supporting that cell-mediated immunity is important for 
suppressing bradyzoite reactivation. Additionally, it has been demonstrated that in vivo 
depletion of CD8+ and CD4+ cells in chronically infected mice results in reactivation of 
Toxoplasma infection [149]. Suppressing IFN-γ production also facilitates bradyzoite 
reactivation during chronic infection in mice [150–152]. In long-term murine astrocyte 
cultures of brain-derived Toxoplasma cysts, the presence of IFN-γ is necessary in order to 
suppress reactivation. Removal of IFN-γ from the culture, 120 days post-infection, resulted 
in cyst rupture and the appearance of cells heavily infected with tachyzoites predominating 
in the culture [153]. One current hypothesis of the mechanism that links IFN-γ with 
supression of reactivation is that IFN-γ may stimulate continuous anti-parasitic activity in 
the astrocytes, causing cell cycle arrest, which has been shown to be associated with 
bradyzoite differentiation [29]. A direct role of the host immune system in repression of 
reactivation remains elusive since even in healthy mice tissue cysts can occasionally rupture, 
releasing invasive parasites that infect new cells [17].
MOLECULAR MECHANISMS
Translational control – downregulation of global translation and preferential translation of 
transcription factors
Given that virtually any type of cellular stress can induce bradyzoite differentiation, and can 
do so independently of the host cell, attention has been directed to the study of stress 
response pathways in the parasite to illuminate the mechanisms driving stage conversion. A 
common response to cellular stress in all eukaryotic organisms is the control of global 
translation via phosphorylation of the alpha subunit of eukaryotic initiation factor 2 (eIF2α). 
Depending on the type of stress the cell is experiencing, one of a number of specific kinases 
is activated to phosphorylate eIF2α, leading to global downregulation of translation with 
concurrent, preferential translation of a subset of mRNAs that code for factors required to 
deal with the stress insult [154]. Recent evidence points to translational control via the 
Toxoplasma homologue of eIF2α, TgIF2α, as a contributing factor in regulating the 
transition of tachyzoite to bradyzoite, maintenance of the dormant bradyzoite, as well as the 
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reactivation of bradyzoites into proliferating tachyzoites, reviewed in [155]. When 
Toxoplasma tachyzoites are subjected to different cellular stresses that are known to induce 
bradyzoite development, TgIF2α becomes phosphorylated [156]. In contrast to intracellular 
replicating tachyzoites, TgIF2α is phosphorylated to a high degree in mature bradyzoites 
[87]. Dephosphorylation of mammalian eIF2α is specifically inhibited by treatment with 
salubrinal or guanabenz [157, 158]. These compounds also inhibit dephosphorylation of 
TgIF2α and treatment of tachyzoites with either salubrinal or guanabenz triggers bradyzoite 
differentiation in vitro [87, 159]. Furthermore, cultured bradyzoite cysts treated with 
salubrinal or guanabenz were no longer able to reactivate into replicating tachyzoites [159].
Once TgIF2α has been phosphorylated, translation is dramatically downregulated [87]. The 
decrease in protein synthesis conserves resources and allows the parasite to reprogram its 
genome to respond accordingly to the stress, which in the case of Toxoplasma, may include 
switching to the latent bradyzoite stage [3]. Discerning which mRNAs are preferentially 
translated while TgIF2α is phosphorylated would be of great use in understanding the 
precise sequence of events and the essential components required for the transition from 
tachyzoite to bradyzoite. Polysome profiling has been used to identify the mRNAs that are 
undergoing translation at a specific timepoint. We have developed a polysome fractionation 
protocol for Toxoplasma combined with microarray analyses, which allowed the 
identification of a subset of mRNAs that are suggested to undergo preferential translation in 
parasites experiencing ER stress as a result of tunicamycin treatment [160]. A number of 
these preferentially translated mRNAs encode proteins containing plant-like AP2 domains, 
which have been identified as the major family of transcription factors in Apicomplexa 
[161]. This set of preferentially translated transcription factors are prime candidates for the 
main effectors upregulating bradyzoite-specific genes and the transition to the dormant cysts.
Transcriptional regulation of bradyzoite-specific genes
Once the switch to cyst development has been triggered, upregulation of bradyzoite-specific 
genes has been observed with a concurrent downregulation of tachyzoite-specific genes. A 
number of studies using different techniques have sought to identify the genome-wide 
changes in gene expression during the bradyzoite developmental program [40, 53, 56, 162, 
163]. Cascades of gene expression are observed as the parasites transition from one stage to 
the next, indicating that transcriptional regulation plays an important role in the regulation of 
stage-switching. A number of these studies also report distinct functional groups of genes 
that are differentially regulated, with surface antigens, metabolic proteins, and secreted 
proteins distinguished with significant differences in expression levels [40, 162]
The initial results from genome sequencing of Toxoplasma and related apicomplexan 
parasites suggested a surprisingly small number of putative transcription factors, prompting 
focus on epigenetic means for gene regulation [164]. However, a growing body of evidence 
indicates that gene expression is regulated by conventional eukaryotic mechanisms. Much of 
the conventional general transcriptional machinery appears to be conserved in Toxoplasma 
[165]. There also appears to be specific DNA motifs for recruitment of factors controlling 
stage-specific gene expression. The promoters of 16 bradyzoite-specific genes were mapped 
to high resolution, which led to the identification of cis-acting elements that appear to be 
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specific to genes induced during differentiation. These elements from the two bradyzoite-
specific genes bag1 and B-NTPase were inserted into the constitutive DHFR-TS promoter 
and converted it into a promoter that enhanced expression of a reporter under bradyzoite-
induction conditions [83].
To identify DNA-associated factors that could function as repressors of bradyzoite gene 
expression during tachyzoite proliferation, pull-downs using the bradyzoite-specific 
promoter ENO1 as bait were performed. This study identified different regulatory factors 
such as an RNA helicase, kinases, phosphatases, and heat shock proteins, as well as a 
number of hypothetical proteins containing domains with high homology to known 
chromatin-association factors. One of the proteins pulled down was an FK506 binding 
protein (FK506BP) homologue called Toxoplasma nuclear factor 3 (TgNF3). TgNF3 
displays a nuclear localization in tachyzoites, but was found to be predominantly 
cytoplasmic in bradyzoites. TgNF3 was shown to associate with both nucleosomes and free 
histones to repress ENO1 and 18S ribosomal RNA genes [166].
The characterization of the ApiAP2 family of plant-like transcription factors in Toxoplasma 
and related apicomplexan parasites [161] has prompted efforts to identify the specific AP2 
factors that may be responsible for coordinating the response to the different signals that 
trigger bradyzoite differentiation (reviewed in [167]). Collation of the various gene 
expression analyses that have been performed on differentiating parasites has identified a 
handful of AP2 factors that are specifically upregulated during bradyzoite development and 
are dampened once the mature tissue cyst is formed [65, 168]. Genetic disruption of these 
AP2 factors is revealing unexpected complexity in the stage transition from tachyzoite to 
bradyzoite, which appears to be mediated by interplay between both activators and 
repressors of bradyzoite genes.
At least two of these AP2 factors, AP2IV-3 and AP2XI-4, function as activators of 
bradyzoite genes [63, 65]. Deletion of AP2XI-4 in both Type I and Type II backgrounds 
generated mutant lines that were unable to initiate expression of bradyzoite marker genes 
during stress [63]. The Type II mutant also displayed a significant defect in cyst formation 
during in vivo infection in mice [63]. AP2IV-3 is also induced early during bradyzoite 
development to promote expression of bradyzoite genes [65]. Knockout of AP2IV-3 reduced 
the rate of cyst formation in response to alkaline stress, while inducible overexpression of 
this factor increased the rate of cyst formation, even in the absence of extrinsic stress. Gene 
expression analysis of the AP2IV-3 overexpressing parasites confirmed upregulation of a 
subset of known alkaline stress-responsive genes [65].
Conversely, another AP2 factor that is upregulated early during bradyzoite development 
AP2IX-9, acts as a repressor of bradyzoite formation. AP2IX-9 knockout parasites have a 
higher rate of spontaneous cyst conversion in normal growth medium and overexpression of 
AP2IX-9 decreased the rate of differentiation under alkaline stress [62, 65]. Both AP2IV-3 
and AP2IX-9 appear to regulate the same target genes and were found to directly associate 
with the chromatin in at least one promoter region (bag1), however further studies are 
required to understand how the action of these antagonistic factors culminates in a decision 
to either continue replication as a tachyzoite, or commit to bradyzoite development.
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Adding to the complexity of tissue cyst development at the molecular level are findings on 
two other AP2 factors that are cell cycle-regulated in tachyzoites. Although not essential for 
tachyzoite replication, AP2IX-4 knockout mutants displayed a defect in cyst formation in 
vitro and in vivo [64]. Localization of AP2IX-4 protein revealed that it is cell-cycle 
regulated and expressed only in dividing parasites, both tachyzoites and bradyzoites. Gene 
expression analysis reveals that AP2IX-4 operates as a repressor of bradyzoite genes during 
alkaline stress, consistent with AP2IX-4 being present in dividing parasites [64]. Similarly, 
another cell cycle regulated factor that peaks at the S/M stage in tachyzoites, AP2IV-4, was 
also identified as a repressor of bradyzoite genes when gene expression analysis on the 
knockout parasites revealed many bradyzoite-specific transcripts to be upregulated [66]. 
Although this mutant line displayed a comparable cyst formation rate to the parental line 
under alkaline stress in vitro, it was completely deficient in tissue cyst formation during 
mouse infection, suggesting that the aberrant expression of bradyzoite proteins early during 
infection primed the host immune response for efficient clearing of the parasite load before 
chronic infection could be established [66]. Collectively, these studies argue against a single 
master regulator of bradyzoite differentiation and suggest that multiple transcription factors 
are involved in fine-tuning gene expression at multiple checkpoints during the transition to 
latency.
The cell cycle and bradyzoite formation
The cyclic regulation of many of the regulators involved in bradyzoite formation suggests 
that this differentiation process is intimately linked to the parasite cell cycle. Early 
experiments showed that when the cell cycle is blocked, differentiation does not proceed 
[169]. Subsequent studies have attempted to elucidate the point in the cell cycle in which the 
tachyzoite switches to the bradyzoite developmental program and which factors play a role 
at this transition point. Gene Set Enrichment Analysis (GSEA) on a number of independent 
gene expression datasets from differentiation experiments provides strong evidence that 
bradyzoite formation and cell cycle regulation are coupled. Genes associated with the S/M 
phase of the cell cycle were more highly enriched in bradyzoites, while genes corresponding 
to the G1 phase were more enriched in tachyzoites [170, 171]. Cell cycle comparison 
between replicating and differentiating tachyzoites identified an enrichment of parasites in 
late S and M stages when bradyzoite development was triggered [95]. Concurrent with this 
observation, microarray analysis at different points in the tachyzoite replication cycle found 
that the levels of a number of bradyzoite-specific transcripts peaked at the late mitotic phase 
of the cell cycle [168]. This was observed in unstressed parasite populations, suggesting that 
even under normal conditions certain factors that are capable of initiating bradyzoite 
development are present, but the master signal for the transition is either absent or 
overpowered by other regulators that drive tachyzoite replication. This evidence supports a 
model whereby tachyzoites pass through a point in the cell cycle in which they are poised 
for development into a bradyzoite. If the signal for bradyzoite development is present, the 
gene expression program for cyst formation proceeds, but in the absence of such stress 
signals, tachyzoite replication continues.
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Changes in the epigenetic landscape for tachyzoite versus bradyzoite genes
A series of studies have demonstrated that epigenetics and histone post-translational 
modifications (PTMs) play a vital role in protozoan parasite biology [63]. More specifically, 
Toxoplasma epigenetics has been linked with the regulation of genes expressed during 
oxidative stress responses, cell cycle, and DNA repair mechanisms, as well as during 
tachyzoite to bradyzoite stage conversion [172–177].
Mining of the Toxoplasma genome has identified a wealth of factors homologous to the 
chromatin remodeling machinery of other well-characterized eukaryotes [164, 176]. 
Additionally, chromatin immunoprecipitation coupled to microarray chip (ChIP-chip) 
experiments have been utilized to determine that H3K4 tri-methylation and H3K9 
acetylation are markers of active promoters in Toxoplasma [178]. The first evidence that 
linked epigenetic regulation with bradyzoite development was the observation that 
nucleosomes present in inactive bradyzoite-specific promoters are hypoacetylated during the 
tachyzoite stage but become acetylated under bradyzoite differentiation conditions [172, 
179]. The converse was shown for tachyzoite-specific genes, whereas constitutively 
expressed genes were hyperacetylated in both developmental stages [172]. The differential 
association of histone deacetylase TgHDAC3 and histone acetyltransferase TgGCN5a at 
stage-specific promoters was also observed using ChIP assays [172]. Specifically, TgGCN5a 
is highly enriched at the promoter regions of transcribed genes [172, 173, 180] while 
TgHDAC3 is found at promoter regions of bradyzoite-specific genes that are silent during 
tachyzoite replication [172]. Moreover, analysis of the transcriptional profile of a TgGCN5a 
KO strain suggested a role for TgGCN5a in triggering bradyzoite gene expression in 
response to alkaline stress. TgGCN5a KO parasites under alkaline treatment did not 
upregulate bag1 or ldh2, and these parasites were deficient in stress recovery [173]. 
Toxoplasma also expresses a second GCN5 histone acetyltransferase homologue, TgGCN5b 
which appears to be crucial during tachyzoite replication, but a role for this enzyme in 
mediating the transition to bradyzoite cyst has yet to be determined [29]. The involvement of 
specific HDACs in differentiation was revealed through the use of the compound FR235222, 
which specifically inhibits TgHDAC3 [174]. Treatment of Toxoplasma-infected cells with 
FR235222 induced bradyzoite differentiation [174]. In addition, comparisons of the 
transcriptional profiles of tachyzoites in the presence or absence of apicidin, another histone 
deacetylase inhibitor, suggested that the tachyzoite to bradyzoite conversion is regulated in 
part through histone acetylation and deacetylation modifications [181]. While these studies 
support the role of histone modifying enzymes in bradyzoite differentiation, it should be 
noted that “histone” modifying enzymes have numerous other substrates whose activity 
could be regulated by acetylation [182, 183].
Chemical inhibitors have also been used to determine the role of methyltransferases in 
Toxoplasma stage differentiation. Specifically, pre-treatment of extracellular tachyzoites 
with AMI-I, an inhibitor of the arginine methyltransferase TgCARM1, induced cyst 
formation [172]. ChIP assays were used to confirm that AMI-I treatment resulted in a 
reduction of H3R17 methylation in the nucleosomes at promoter regions of tachyzoite-
specific genes, suggesting an important function of the H3R17 mark for tachyzoites [172]. 
However, methylation of H3R17 can also be observed in in vitro bradyzoites, pointing to a 
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key function for TgCARM1 in both stages. A significant gene duplication event and 
subsequent divergence in the SET-containing domain histone lysine methyltransferases has 
been reported in Toxoplasma [175]. TgSET8 was shown to be enriched in heterochromatic 
regions such as silenced rRNA genes, satellite repeats, and telomeric sites, with the 
repressive methylation marks H3K9 and H4K20 [175]. Notably, increased H4K20me1 levels 
have been detected in bradyzoite containing cysts purified from mice [175], indicating that 
TgSET8 may facilitate the maintenance of the chronic stage inside the host.
An interesting family of chromatin remodelers that has not been studied extensively, but has 
been linked to epigenetic regulation of stage conversion, is the SWI/SNF ATP-dependent 
nucleosome remodeling complexes. Intriguingly, the Toxoplasma genome has 17 predicted 
members of this family [176]. The mRNA from one member of this family, TgSRCAP 
(Snf2-Related CBP Activator Protein), is upregulated during in vitro bradyzoite stage 
conversion [184]. As previously mentioned, another member of this family, TgRSC8, was 
identified in an insertional mutagenesis screen designed to select for mutants defective in 
bradyzoite formation [41, 185].
Changing nucleosome composition is an additional mechanism that may be used to control 
gene expression during stage conversion in Toxoplasma. In addition to the canonical 
histones H2A and H2B, the Toxoplasma genome encodes a number of histone H2 variants, 
denoted H2AX, H2AZ, and H2Bv [164]. H2Bv forms dimers with H2A.Z on the promoter 
regions of active genes [186]. Notably, the incidence of H2A.Z changes in relation to the 
transcriptional status of a gene; preliminary data showed that H2A.Z is positioned within the 
coding region of silent bradyzoite-specific genes and within promoter regions but not coding 
regions of actively expressed genes [187]. In contrast, H2AX is enriched at promoters of 
repressed genes as well as within silent genomic regions in tachyzoites [186]. Furthermore, 
the expression levels of H2AX are increased during in vitro bradyzoite formation, 
suggesting that H2AX may facilitate global gene repression during the latent bradyzoite 
stage [186].
Multiple approaches have demonstrated the importance of epigenetic regulation during the 
transition from tachyzoite to bradyzoite. Many of the fundamentals of epigenetic regulatory 
mechanisms appear to be well preserved in parasites. However, there is a surprisingly high 
diversity within the proteins that constitute the chromatin remodeling machinery in 
Toxoplasma. PTM-histone mapping studies [187] as well as characterization of “species-
specific” and “stage-specific” epigenetic modifications of Toxoplasma will assist in 
elucidating the complete mechanism of the complex developmental pathway driving 
bradyzoite formation.
CONCLUSION AND FUTURE DIRECTIONS
The ability of Toxoplasma to form latent cysts and persist in the host for many years is the 
key to the parasite’s successful dissemination throughout a large proportion of the human 
population and numerous animal hosts worldwide.
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We are beginning to understand the early stages of the transition from tachyzoite to 
bradyzoite induced by stress, but further research is required to flesh out the mechanisms 
involved. Importantly, these mechanisms need to be compared to newer models of in vitro 
differentiation that do not require the application of exogenous stress (i.e. spontaneous 
differentiation). Recent advances have identified a number of AP2 and chromatin 
remodeling factors that are responsible for controlling the gene expression program as the 
parasites switch from tachyzoite to bradyzoite, but how they are engaged and how they 
interplay remains largely unresolved. Many elements are at work in this complex, 
multifactorial process and advances in the molecular tools for cystogenic Toxoplasma strains 
will help to address remaining questions.
An area that has been largely neglected to date is the process of reactivation and how the 
parasite re-enters the proliferative tachyzoite cycle after dormancy. Phosphorylation of 
TgIF2α appears to play a crucial role in perpetuating quiescence of the bradyzoites within 
the cyst and tantalizing new studies demonstrate that pharmacological interference with 
translational control can impede tachyzoite growth and the reactivation of infection [159].
Ultimately, we will require a detailed understanding of the signaling processes required for 
bradyzoite formation to interrupt the tachyzoite-bradyzoite transition. Definition of these 
pathways may enable us to chemically target central mediators of the differentiation and 
latency processes, and allow development of novel therapies for the individuals at risk of 
toxoplasmosis.
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Figure 1. 
A five day old, in vitro bradyzoite cyst induced under alkaline conditions, stained with 
fluorophore-linked lectin from Dolichos biflorus (red), which binds to the polysaccharide-
rich cyst wall. Blue: 4′,6-diamidino-2-phenylindole, DAPI (nucleus). Scale bar, 10μm. 
Labelled schematic depicts the stained tissue cyst in the infected host cell.
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Table 1
Genes associated with bradyzoite development or maintenance in Toxoplasma.
Name ToxoDB ID Function Reference
CST1 TGME49_264660 (SRS44) Cyst wall glycoprotein, recognized by Dolichos biflorus lectin. [28, 33, 34]
MAG1 TGME49_270240 Cyst wall and matrix protein, bradyzoite specific marker. [37]
BPK1 TGME49_253330 Cyst wall protein. In bpk1 strain cysts are smaller and more 
sensitive to pepsin-acid bpk1 strain has reduced ability to cause 
oral infection. treatment;
[39]
MCP4 TGME49_208730 Cyst wall protein. [40]
PPG1 TGME49_297520 Serine/proline-rich proteophosphoglycan (GU182879), this gene 
has a role in cyst wall formation.
[41]
SAG4 (or SRS35B) TGME49_280570 SAG-family related surface protein of bradyzoite. [52]
BSR4 (or SRS16C) TGME49_320180 SAG-family related surface protein of bradyzoite. [55]
SAG2C (or SRS49D) TGME49_207160 SAG-family related surface protein of bradyzoite. [188, 189]
SAG2D (or SRS49C) TGME49_207150 SAG-family related surface protein of bradyzoite. [188, 189]
SAG2Y (or SRS49A) TGME49_207130 SAG-family related surface protein of bradyzoite. The transcript 
is upregulated in bradyzoites. Δsag2y forms cysts both in vitro 
and in vivo but demonstrates a defect in persistence in vivo.
[190]
SAG2X (or SRS49B) TGME49_207140 SAG-family related surface protein of bradyzoite. The transcript 
is upregulated in bradyzoites. Δsag2x forms cysts both in vitro 
and in vivo but demonstrates a defect in persistence in vivo.
[190]
SRS9 (or SRS16B) TGME49_320190 SAG-family related surface protein of bradyzoite. [60]
BRP1 TGME49_314250 Bradyzoite rhoptry protein 1, localized in rhoptries of bradyzoites 
and found to be secreted in PV of in vitro bradyzoites. Δbrp1 
strain develops and establishes both acute and chronic infection 
normally.
[191]
HSP60 TGME49_247550 Mitochondrial heat shock protein, member of mitochondria 
chaperone family. HSP60 transcript is highly increased in 
bradyzoites. The protein is localized in two vesicular bodies 
distinct from the mitochondrion in encysted bradyzoites.
[50]
hsp30/BAG1 (BAG1) TGME49_259020 Small heat shock protein, bradyzoite specific marker, not 
necessary for cyst formation.
[43, 45]
LDH2 TGME49_291040 Lactate dehydrogenase 2 is a glycolytic enzyme upregulated in 
bradyzoites. Δldh2 parasites form fewer brain cysts.
[46, 47, 74]
ENO1 TGME49_268860 Bradyzoite-specific Enolase 1, functions in glycolysis [73]
PMA1 TGME49_252640 P type ATPase, upregulated in bradyzoite stage. The protein is 
localized in the membrane of mature bradyzoites purified from 
brain tissue cysts of chronically infected mice. The pma-1 strain 
has reduced ability to form bradyzoites in response to a number 
of different in vitro triggers, but is still capable of establishing 
chronic infection in mice.
[51, 59]
AP2XII-6 TGME49_249190 Putative transcription factor. The insertional mutant on this locus 
is defective in upregulating bradyzoite markers during in vitro 
induction.
[82]
AP2XI-4 TGME49_315760 Putative transcription factor. Δap2xi-4 parasites are unable to 
express many genes including some bradyzoite markers during 
pH stress differentiation, and have defects in cyst formation in 
mice.
[63]
AP2IX-9 TGME49_306620 Transcription factor that represses bradyzoite formation. Δap2ix-9 
parasites have enhanced ability to form cysts in vitro. 
Overexpression of AP2IX-9 inhibits bradyzoite formation.
[62, 65]
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Name ToxoDB ID Function Reference
AP2IX-4 TGME49_288950 Cell cycle regulated transcription factor that represses expression 
of bradyzoite genes. Δap2ix-4 parasites have reduced ability to 
form cysts under alkaline stress in vitro.
[64]
AP2IV-3 TGME49_ 318610 Transcription factor that is induced during bradyzoite 
development and promotes expression of bradyzoite specific 
genes. Overexpression of TgAP2IV-3 enhances bradyzoite 
formation in vitro.
[65]
AP2IV-4 TGME49_318470 Cell cycle-regulated transcription factor that represses bradyzoite-
specific transcripts during tachyzoite development. Parasites 
lacking this factor do not form cysts in mouse brain tissue.
[66]
GRA1 TGME49_270250 Dense granule protein. In the cyst, GRA1 is localized in the cyst 
wall and the cyst matrix. Unknown function.
[23, 34, 35]
GRA3 TGME49_227280 Dense granule protein. In the cyst, GRA3 is localized in the cyst 
wall. Unknown function.
[23, 34, 35]
GRA5 TGME49_286450 Dense granule protein. In the cyst, GRA5 is localized at the cyst 
wall membrane. Unknown function.
[23, 34, 42, 
192 ]
GRA6 TGME49_275440 Dense granule protein. In the cyst, GRA6 is localized in the cyst 
wall. Unknown function.
[23, 34, 35]
GRA7 TGME49_203310 Dense granule protein. In the cyst, GRA6 is localized in the cyst 
wall. Unknown function.
[36]
Splicing factor, arginine/
serine rich
TGME49_213635 Putative splicing factor. The insertional mutant on this locus is 
defective in bradyzoite differentiation in vitro.
[82]
OWP1 TGME49_204420 Annotated as putative oocyst wall protein. The insertional mutant 
on this locus is defective in bradyzoite differentiation in vitro.
[82]
Replication factor A 
protein 3
TGME49_238110 Function unknown. The insertional mutant on this locus is 
defective in bradyzoite differentiation in vitro.
[82]
PUS1 TGME49_202640 Pseudouridine synthase homolog. Two insertional mutants on this 
locus are defective in tachyzoite to bradyzoite differentiation in 
vitro. Infection with pus-1 parasites results in higher mortality 
and increased cyst burden.
[70]
ZFP1 TGME49_218362 Nucleolar CCHC motif zinc-finger protein 1. Both the insertional 
mutant and the zfp1 strain have impaired differentiation in vitro 
and fail to upregulate bradyzoite specific transcripts.
[69]
Tg-ncRNA-1 TGME49_238110 Non coding RNA 1. Insertional mutants on this locus show 
differentiation defects and reduced cyst loads.
[71, 193]
TgRRS1 TGME49_320450 Ribosome biogenesis regulatory protein 1 that it localized to the 
nucleolus. Two insertional mutants in tgrrs1 are defective in 
bradyzoite formation in vitro.
[194]
DNA primase subunit, 
large subunit
TGME49_297840 Function unknown. The insertional mutant on this locus is 
defective in bradyzoite in vitro. differentiation
[82]
TBC domain containing 
protein
TGME49_285730 Function unknown. The insertional mutant on this locus is 
defective in bradyzoite differentiation in vitro.
[82]
HECT-domain 
(ubiquitin-transferase) 
domain-containing 
protein
TGME49_270580 Function unknown. The insertional mutant on this locus is 
defective in bradyzoite differentiation in vitro.
[82]
Supt5 TGME49_233300 Rho-GAP domain containing protein, transcription elongation 
factor. The insertional mutant on this locus is defective in 
bradyzoite differentiation in vitro.
[82]
TgSRCAP TGME49_280800 SWI/SNF-like factor, which is upregulated during bradyzoite 
differentiation.
[184]
TgRSC8 TGME49_286920 SWI/SNF-like factor. An insertional mutantwith reduced protein 
levels of TgRSC8 expresseslower levels of some bradyzoite 
specific transcripts during in vitro induction.
[41, 185]
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Name ToxoDB ID Function Reference
eIF2-α TGME49_286420 Homologue of the alpha subunit of the eukaryotic initiation factor 
2. eIF2-α is highly phosphorylated in bradyzoites. Important 
factor in regulation of bradyzoites differentiation and 
maintenance as well as in reactivation of bradyzoites to 
tachyzoites.
[87, 155, 156, 
195]
HDAC3 TGME49_227290 Histone deacetylase 3, the protein is highly enriched in promoters 
of silent genes. Chemical inhibition of HDAC3 induced 
bradyzoite differentiation in vitro.
[172, 174]
GCN5a TGME49_254555 Histone lysine acetyltransferase A. Transcriptional analysis of 
Δgcn5a parasites demonstrates a role for TgGCN5a in 
upregulating bradyzoite transcripts in vitro.
[172, 173]
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